Welcome to our dedicated page for JOHNSON & JOHNSON SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson is asking shareholders at its April 23, 2026 virtual annual meeting to elect 12 directors, approve executive pay on an advisory basis, ratify PricewaterhouseCoopers as 2026 auditor, and vote on a shareholder proposal for an independent board chair, which the Board recommends against.
The Board remains mostly independent, with a combined Chairman/CEO structure balanced by a powerful Lead Independent Director role and fully independent key committees. The proxy details board refreshment, committee responsibilities, Enterprise Risk Management, cybersecurity and sustainability oversight, and a pay-for-performance program heavily weighted to long-term equity incentives.
Directors and executives show meaningful stock ownership and strong Say on Pay support in 2025, while large institutional holders such as Vanguard, BlackRock and State Street are disclosed. The Board highlights active shareholder engagement and oversight of a potential separation of the Orthopaedics business through a Special Committee.
Johnson & Johnson executive Robert J. Decker, VP Corporate Controller, exercised employee stock options for 4,075 shares of common stock on February 27, 2026 and immediately received those shares at an exercise price of $115.67 per share. He then sold 4,075 shares of common stock the same day in an open-market transaction at an average price of $247.87 per share, leaving him with 23,682 shares of common stock held directly.
In addition to his direct holdings, Decker is reported as having 134 shares of common stock held indirectly through an ESOP under the Johnson & Johnson Savings Plan and 646 shares held indirectly through a 401(k) plan, both as of the plans’ most recent reporting date of February 28, 2026.
Johnson & Johnson EVP Timothy Schmid reported an open-market sale of 1,322 shares of common stock at $245.66 per share on February 20, 2026. After this transaction, he directly held 25,447 shares of Johnson & Johnson.
He also reported indirect holdings of 46 shares through an ESOP under the Johnson & Johnson Savings Plan and 745 shares through a 401(k), both based on the plan’s most recent reporting date of January 31, 2026.
Johnson & Johnson insider sale reported. The filing shows a sale of 22,623 common shares by Timothy Schmid on 02/18/2026 for $5,527,545.45. The form also lists a restricted stock vesting of 1,322 shares on 02/13/2026. A broker listed is Fidelity Brokerage Services LLC with an entry date of 02/20/2026.
Johnson & Johnson executive James D. Swanson reported a series of equity compensation transactions and related share sales. On February 13–17, 2026, he exercised employee stock options, restricted share units (RSUs), and performance share units (PSUs) into Johnson & Johnson common stock, with prices on certain option exercises around $162.75–$165.89 per share.
Swanson then conducted open-market sales totaling 62,080 shares of common stock at weighted average prices around $242.70–$243.76, while additional shares were withheld to cover tax obligations upon RSU and PSU vesting. Following these transactions, he directly owned 25,698.131 shares of Johnson & Johnson common stock.
Separately, on February 15, 2026, he received new equity awards under the company’s Long-Term Incentive Plan, including 19,449 employee stock options and 1,397 RSUs, which vest in three equal annual installments and convert into common stock on a one-for-one basis upon vesting.
Johnson & Johnson executive Kathryn E. Wengel, EVP and Chief TO and Risk Officer, reported multiple equity compensation transactions. She exercised vested restricted share units and performance share units into common stock on February 13 and 15, 2026, and received new grants of restricted share units and employee stock options under the company’s Long-Term Incentive Plan.
On those dates she acquired common shares through derivative exercises and awards, while a portion of the resulting shares was withheld at prices of $243.45 and $244.55 per share to cover tax obligations, which is disclosed as share dispositions. After these transactions, she held 113,977.8735 common shares directly, plus additional indirect holdings in the Johnson & Johnson Savings Plan and ESOP.
Johnson & Johnson EVP and Chief HR Officer Kristen Mulholland reported equity compensation activity involving restricted share units, performance share units, stock options, and common stock. On February 15, 2026 she received grants of 20,322 employee stock options and 1,459 restricted share units, all at a stated price of $0.0000 per unit, under the company’s Long-Term Incentive Plan.
On the same date, previously granted restricted share units converted into 419 and 575 shares of common stock, increasing her direct holdings. Some of these new shares were withheld at prices of about $243.45 per share to cover tax obligations, reported with transaction code F as tax-withholding dispositions, rather than open-market sales.
On February 13, 2026, earlier grants of restricted share units and performance share units from prior years also converted into common stock. Those conversions added blocks of 410 and 3,602 common shares, followed by additional F-coded dispositions at around $244.55 per share to satisfy taxes due upon vesting. After these transactions, she continued to hold common stock directly, with the filing showing updated post-transaction balances for each line item.
JOHNSON & JOHNSON Executive VP and CFO Joseph J. Wolk reported multiple equity award transactions and sales. He exercised stock options, performance share units, and restricted share units into common stock on February 13, 15, and 17, 2026, and received new grants of 53,793 employee stock options and 3,863 restricted share units under the company’s long‑term incentive plan.
On February 17, 2026, he sold 89,654 shares of common stock in open‑market transactions and also disposed of shares to cover tax obligations upon vesting of awards. After these transactions, direct ownership entries show 14,000 common shares, alongside indirect holdings of 68,835 shares in a spousal lifetime access trust and 2,173 shares in a 401(k) plan.